TY - JOUR
T1 - Long term outcomes of patients transplanted for hepatocellular carcinoma with human immunodeficiency virus infection
AU - Eman, P.
AU - Chacon, Eduardo
AU - Gupta, M.
AU - Berger, Jonathan C.
AU - Shah, Malay B.
AU - El Haddad, Hanine E.
AU - El-Husseini, Amr
AU - Dela Cruz, Anna C.
AU - Grigorian, Alla
AU - Mei, Xiaonan
AU - Gedaly, Roberto
N1 - Publisher Copyright:
© 2019 International Hepato-Pancreato-Biliary Association Inc.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/8
Y1 - 2019/8
N2 - Background: We aimed to study outcomes in HIV + patients with HCC in the US following Liver Transplantation (LT) using the UNOS dataset. Methods: The database was queried from 2003 to 2016 for patients undergoing LT with HCC, HIV+, and HCC/HIV+. Results: Out of 17,397 LT performed for HCC during the study period, 113 were transplanted for HCC with HIV infection (91 isolated livers). Patients transplanted for HCC/HIV+ were younger (55.54 ± 5.89 vs 58.80 ± 7.37, p < 0.001), had lower total bilirubin (1.20 vs 1.60, p = 0.042) significantly lower BMI (25.35 ± 4.43 vs 28.39 ± 5.17, p < 0.001) and were more likely to be co-infected with HBV (25.3% vs 8.2% p < 0.001) than those transplanted for HCC alone. HCC/HIV + patients were found to have a 3.8 fold increased risk of peri-operative mortality at 90 days after matching. HCC/HIV + recipients had 54% decreased long-term survival within the HCC cohort. Our initial analysis of overall graft and patient survival found significant differences between HCC/HIV– and HCC/HIV + recipients. However, these variances were lost after case-matching. Recurrence and disease free survival were similar in HCC alone vs HCC/HIV + recipients. Conclusions: Our analysis suggests that excellent outcomes can be achieved in selected patients with HCC/HIV+.
AB - Background: We aimed to study outcomes in HIV + patients with HCC in the US following Liver Transplantation (LT) using the UNOS dataset. Methods: The database was queried from 2003 to 2016 for patients undergoing LT with HCC, HIV+, and HCC/HIV+. Results: Out of 17,397 LT performed for HCC during the study period, 113 were transplanted for HCC with HIV infection (91 isolated livers). Patients transplanted for HCC/HIV+ were younger (55.54 ± 5.89 vs 58.80 ± 7.37, p < 0.001), had lower total bilirubin (1.20 vs 1.60, p = 0.042) significantly lower BMI (25.35 ± 4.43 vs 28.39 ± 5.17, p < 0.001) and were more likely to be co-infected with HBV (25.3% vs 8.2% p < 0.001) than those transplanted for HCC alone. HCC/HIV + patients were found to have a 3.8 fold increased risk of peri-operative mortality at 90 days after matching. HCC/HIV + recipients had 54% decreased long-term survival within the HCC cohort. Our initial analysis of overall graft and patient survival found significant differences between HCC/HIV– and HCC/HIV + recipients. However, these variances were lost after case-matching. Recurrence and disease free survival were similar in HCC alone vs HCC/HIV + recipients. Conclusions: Our analysis suggests that excellent outcomes can be achieved in selected patients with HCC/HIV+.
UR - http://www.scopus.com/inward/record.url?scp=85061256922&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061256922&partnerID=8YFLogxK
U2 - 10.1016/j.hpb.2019.01.001
DO - 10.1016/j.hpb.2019.01.001
M3 - Article
C2 - 30765199
AN - SCOPUS:85061256922
VL - 21
SP - 1009
EP - 1016
IS - 8
ER -